Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

London biotech secures £90 million backing

Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers

Evening Standard

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients

A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.

Investors Business Daily

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo, Lilly Fall After Biden Slams Duo For 'Unconscionably High' Drug Prices

Novo Nordisk stock fell Tuesday after Joe Biden and Bernie Sanders slammed the drugmaker and Eli Lilly for high prices of weight-loss drugs.

Investors Business Daily

Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs

Cartesian Therapeutics reported a "watershed moment" for its autoimmune-disease drug on Tuesday, but the biotech stock plunged.

Investors Business Daily

3 Mid-Cap Stocks Analysts Believe Will Soar 50% or More

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

StockNews.com

US Supreme Court Rejects Opioid Settlement That Shields Sackler Family

The US Supreme Court on Thursday rejected Purdue Pharma's $6 billion opioids settlement immunizing the Sackler family, which controlled the drugmaker, from future litigation.

International Business Times

Read news from The Economist, FT, and more,
with one subscription

Walgreens will close a ‘significant’ number of failing stores across US

There are 8,500 Walgreens stores across the country, and around a quarter are failing

The Independent UK

Supreme Court rejects settlement with OxyContin maker Purdue Pharma over legal protections for the Sackler family that owned the company

The Supreme Court ruled 5-4 against an estimated US$6 billion Purdue Pharma bankruptcy plan on June 27, 2024, that would have shielded the Sackler family – which owned and controlled the company – from legal liability.

The Conversation

US Supreme Court rejects $6 billion OxyContin settlement shielding Sackler family

The US Supreme Court on Thursday rejected OxyContin maker Purdue Pharma's $6 billion settlement that would have shielded the Sackler family, who owned the company and earned tens of billions as it flooded the country with the highly addictive drug, from future civil lawsuits over the role they played in…

France 24

Drug Distributor Cencora Falls; Blame Walgreens, Not The Supreme Court

Cencora stock and other drug distributors fell on Wednesday, hit by Walgreens results, not the ruling that killed an opioid settlement.

Investors Business Daily

Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection

Merck stock tumbled under its 50-day moving average Thursday after the FDA rejected its Daiichi Sankyo-partnered cancer drug.

Investors Business Daily

The legal odyssey for OxyContin maker Purdue Pharma and its owners is complex. Here's what to know

The Supreme Court has rejected a settlement for OxyContin maker Purdue Pharma and members of the Sackler family who own the company

The Independent UK

Fluffy's Drugmaker Elanco Animal Health Plummets On Unexpected Safety Warning

Elanco stock plummeted Thursday after the company announced a pair of delays and a surprise warning for its new eczema treatment for dogs.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Supreme Court shreds nationwide $6 billion opioid settlement plan in ruling against Sackler family

The Supreme Court said the Sackler family cannot use a Chapter 11 reorganization plan to protect themselves from civil liability

The Guardian - US

US supreme court blocks Purdue Pharma’s bankruptcy settlement that would shield Sacklers from lawsuits

Controversial deal would have protected billionaire family owners from further liability over US opioid epidemic

The Independent UK

Walgreens to take a hard look at underperforming stores, could shutter hundreds more

Walgreens is finalizing a plan to fix its business that could result in the closure of hundreds of additional stores in the next three years

The Independent UK

The Supreme Court rejects a nationwide opioid settlement with OxyContin maker Purdue Pharma

The Supreme Court has rejected a nationwide settlement with OxyContin maker Purdue Pharma that would've shielded Sackler family members who own the company from civil lawsuits over the toll of opioids but also would've provided billions of dollars to combat the epidemic

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stocks To Watch: Biotech Leader TG Therapeutics Clears Resistance Area

Among the best stocks to watch, biotech leader TG Therapeutics is clearing a key resistance area on the stock market today.

Investors Business Daily

How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park'

Blueprint Medicines is Tuesday's IBD Stock Of The Day. Shares are breaking a trendline, giving investors an early entry within a flat base.

Investors Business Daily

Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling

This biotech stock nears a buy point after an explosive move following positive drug trial news. Sales have grown by triple-digits for seven quarters.

Tom’s Hardware

Organ-on-chip market for drug testing expected to see tenfold growth to $1.3 billion by 2032

Pharmaceutical and cosmetic companies are the number one consumers of this tech, but other industries are taking notice.

The Guardian - UK

Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy

The Guardian - AU

Pharmacists say they were not consulted on ‘rushed’ Labor-Greens vape deal

Federal health minister counters that Pharmacy Guild did not make submission to regulation inquiry and selling vapes still a decision for individual stores

Kiplinger

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.